Roivant Sciences Ltd.
ROIV
71 insider filings · Latest: Oct 1, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Oct 5 10:05 PM | Melissa B, EpperlyDirector | Sale | 17,750 | $36.10 | $640.9K | 14,954(D) | View → |
| Sep 30, 2026 | Oct 2 9:37 PM | Eric VenkerPresident & Immunovant CEO | Sale | 200,000 | $36.62 | $7.3M | 1,599,154(D) | View → |
| Sep 30, 2026 | Sep 30 8:21 PM | Venker Eric | Proposed Sale | 200,000 | $36.62 | $7.3M | — | View → |
| Sep 15, 2026 | Sep 17 10:43 PM | Melissa B, EpperlyDirector | Sale | 4,938 | $39.74 | $196.2K | 9,900(D) | View → |
| Sep 15, 2026 | Sep 17 10:42 PM | Meghan FitzgeraldDirector | Sale | 5,112 | $39.74 | $203.2K | 36,108(D) | View → |
| Sep 15, 2026 | Sep 15 8:40 PM | MELISSA EPPERLY | Proposed Sale | 22,688 | $41.02 | $930.7K | — | View → |
| Sep 15, 2026 | Sep 15 8:32 PM | MEGHAN FITZGERALD | Proposed Sale | 5,112 | $41.02 | $209.7K | — | View → |
| Sep 8, 2026 | Sep 11 1:00 AM | Meghan FitzgeraldDirector | Sale | 20,000 | $39.90 | $798.0K | 42,963(D) | View → |
| Sep 8, 2026 | Sep 8 8:27 PM | MEGHAN FITZGERALD | Proposed Sale | 20,000 | $34.93 | $698.6K | — | View → |
| Aug 28, 2026 | Sep 2 1:00 AM | Eric VenkerPresident & Immunovant CEO | Sale | 200,000 | $35.77 | $7.2M | 1,599,154(D) | View → |
| Aug 28, 2026 | Aug 28 8:33 PM | Venker Eric | Proposed Sale | 200,000 | $35.74 | $7.1M | — | View → |
| Aug 21, 2026 | Aug 22 1:00 AM | Mayukh SukhatmeDirector, President & CIO | Sale | 144,756 | $36.48 | $5.3M | 18,630,739(D) | View → |
| Aug 20, 2026 | Aug 22 1:00 AM | Mayukh SukhatmeDirector, President & CIO | Sale | 17,519 | $37.30 | $653.5K | 18,630,739(D) | View → |
| Aug 19, 2026 | Aug 22 1:00 AM | Mayukh SukhatmeDirector, President & CIO | Sale | 172,899 | $37.17 | $6.4M | 18,630,739(D) | View → |
| Aug 21, 2026 | Aug 21 8:20 PM | MAYUKH SUKHATME | Proposed Sale | 144,756 | $36.48 | $5.3M | — | View → |
| Aug 20, 2026 | Aug 20 8:34 PM | MAYUKH SUKHATME | Proposed Sale | 17,519 | $37.30 | $653.4K | — | View → |
| Aug 19, 2026 | Aug 19 8:23 PM | MAYUKH SUKHATME | Proposed Sale | 172,899 | $37.17 | $6.4M | — | View → |
| Aug 18, 2026 | Aug 19 1:00 AM | Mayukh SukhatmeDirector, President & CIO | Sale | 136,942 | $36.73 | $5.0M | 18,630,739(D) | View → |
| Aug 17, 2026 | Aug 19 1:00 AM | Mayukh SukhatmeDirector, President & CIO | Sale | 284,707 | $36.25 | $10.3M | 18,630,739(D) | View → |
| Aug 14, 2026 | Aug 19 1:00 AM | Mayukh SukhatmeDirector, President & CIO | Sale | 243,177 | $36.23 | $8.8M | 18,630,739(D) | View → |
Page 1 of 8
Next →
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | Jun 29 10:23 PM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 500,000 | $3.85 | 14,724,363(D) | View → |
| Jun 24, 2026 | Jun 26 10:13 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,244,834(D) | View → |
| May 22, 2026 | May 22 10:25 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,444,834(D) | View → |
| Apr 20, 2026 | Apr 22 10:27 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,644,834(D) | View → |
| Apr 20, 2026 | Apr 22 10:26 PM | Richard PulikCFO | Grant/Award | 84,026 | $29.08 | 84,026(D) | View → |
| Apr 20, 2026 | Apr 22 10:26 PM | Jennifer HumesChief Accounting Officer | Grant/Award | 27,157 | $29.08 | 27,157(D) | View → |
| Mar 30, 2026 | Apr 1 11:20 PM | Matthew GlineDirector, CEO | Option Exercise | 2,178,150 | — | 0(D) | View → |
| Mar 30, 2026 | Apr 1 11:19 PM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 1,306,889 | — | 0(D) | View → |
| Mar 26, 2026 | Mar 31 1:01 AM | Meghan FitzgeraldDirector | Option Exercise | 70,000 | $8.80 | 48,578(D) | View → |
| Mar 17, 2026 | Mar 19 10:36 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,844,834(D) | View → |
| Feb 23, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Option Exercise | 587,390 | $3.85 | 3,026,184(D) | View → |
| Feb 20, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Option Exercise | 1,012,610 | $3.85 | 3,613,574(D) | View → |
| Feb 19, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Option Exercise | 1,400,000 | $3.85 | 4,626,184(D) | View → |
| Feb 13, 2026 | Feb 18 10:57 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 5,044,834(D) | View → |
| Feb 9, 2026 | Feb 11 10:53 PM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 651,558 | $12.68 | 0(D) | View → |
← Previous
Page 2 of 2